James Legg
Chief Scientific Officer Cytospire Therapeutics Ltd
Seminars
Monday 8th June 2026
Unlocking the Full Potential of Gamma Delta T-Cells: A New Class of Multispecific Engagers for Solid Tumours
5:00 pm
- Gamma delta T-cells combine innate potency with adaptive durability, enabling rapid and sustained immune responses that are naturally suited to discriminating diseased from healthy cells
- Gamma delta T-cell engagers leverage this unique biology to activate tumour-relevant effector cells while avoiding broad immune activation, supporting effective tumour killing with a lower risk of cytokine-driven toxicity
- Cytospire’s multispecific TCE platform activates all gamma delta T-cell subsets, including tissue-resident populations, overcoming patient heterogeneity to unlock more consistent, scalable efficacy in solid tumours
